Lam Research Corp.

FREMONT, Calif., March 30, 2023 /PRNewswire/ -- Lam Research Corp. (NASDAQ: LRCX) today announced that the company will host its quarterly financial conference call and webcast on Wednesday, April 19, 2023, beginning at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). About Lam Research Lam Research Corporation (NASDAQ: LRCX) is a global supplier of innovative wafer fabrication equipment and services to the semiconductor industry. Lam's equipment and services allow customers to build smaller and better performing devices. In fact, today, nearly every advanced chip is built with Lam technology. We combine superior systems engineering, technology leadership, and a strong values-based culture, with an unwavering commitment to our customers. Lam Research is a FORTUNE 500® company headquartered in Fremont, California, with operations around the globe. Learn more at (LRCX-F). Ram Ganesh Investor Relations (510) 572-1615 [email protected] Source: Lam Research Corporation, (Nasdaq: LRCX) SOURCE Lam Research Corporation

DUBLIN, June 23, 2022 /PRNewswire/ -- The "Microneedle Measurable Chronic Disease Biomarkers" report has been added to ResearchAndMarkets.com's offering. Biomarkers are a key medical product development tool capable of facilitating development of medical products and spurring innovation. When used in the right context, biomarkers have the potential to help expedite patient access to safe and effective treatments by reducing the time and cost of clinical trials while maintaining patient protections. FDA encourages the integration of biomarkers in medical product development and approval, to facilitate the monitoring of FDA-regulated products, and their appropriate use in clinical practice. Biomarkers promise to reduce stagnation and foster innovation in the development of new medical products. A biomarker can be used as the basis for creating a routine diagnostic test for clinical use, after it has been approved as an in-vitro diagnostic. A biomarker can also be used to develop a companion diagnostic test that enables better decision-making on the use of a therapy that is tailored to the patient. Biomarkers are biochemical molecules that indicate how the human body may react to certain active pharmaceutical ingredients (APIs) or different types of environmental factors. A simple but well-known example of the role of biomarkers in patient health and well-being would be food allergies. By identifying biomarkers in human physiology and understanding their role in drug therapy, allergies and immune reactions, caregivers are better able to help patients avoid drug side effects and to determine when a particular drug will produce the desired therapeutic effect for a given patient. The FDA has assembled a database titled Table of Pharmacogenomic Biomarkers in Drug Labeling. This information resource illustrates identified relationships between drugs and biomarkers. Knowing which patients exhibit certain types of biomarkers is therefore desirable. Researchers and investigators are interested in finding ways to identify, measure and quantify biomarkers in ways that are non-invasive, or at least minimally invasive to minimize any discomfort to the patient. Microneedles are one of the ways being explored to sample, measure and quantify biomarkers for specific diseases. Using microneedles to collect biomarkers in the interstitial fluid (ISF) can be an inexpensive and rapid method for assessing the role of biomarkers in therapeutics and disease management. This report covers these areas and describes the current state of technology. What You Will Learn What companies are active in the microneedle diagnostics segments, what distinguishes their technology, and what is their market presence? What are the identified and verified chronic disease biomarkers, and what are their properties ? What are the major factors that are influencing interest in chronic disease biomarkers? What are the design factors, material selection issues, technologies, and market development issues for microneedles capable of capturing and identifying chronic disease biomarkers? What are the important therapeutic markets for microneedle measurable chronic disease biomarkers? What is their market potential? What are the significant economic, technology, and regulatory factors affecting the market for diagnostic microneedles? Key Topics Covered: Executive Summary Microneedle Measurable Chronic Disease Biomarkers Point-of-Care Diagnostics Market Dynamics Biomarkers and their Potential in Clinical Medicine Microneedles for Detecting and Measuring Biomarkers Microneedle Product Categories Solid Microneedles Hollow Microneedles Coated Microneedles Dissolving Microneedles Stretched Needles Carbon Nanotubes Ion Etching C-MEMS Specialty Microneedles Phase Transition Microprocessor-based Devices Composite Microneedles Light-responsive Microneedles Flexible Arrays Microneedle Arrays & Array Geometries Array Architectures Microneedles & Microfluidics Wearable Microneedles The Role of Interstitial Fluid Microneedle Diagnostics - Design Factors Analyte Capture Sample Acquisition Biofluid Absorption Electrochemical Sensing Methods Optical Sensing Methods Chronic Disease Associated Biomarkers Biomarker Detection Microneedle Fabrication Micromolding Microforming Micromachining Structured Films Emerging Fabrication Methods 3D Printing Electrospun Arrays Two-Photon Polymerization (2PP) Magnetization-induced Self-assembly Additive Fabrication Methods Stereolithography Fused Deposition Modelling Digital Light Processing Selective Laser Sintering Selective Laser Melting Inkjet Printing Surface Modification Diagnostic Microneedle Device Analysis Micro Transdermal Interface Platform (MicroTIPs) Mindera Health Scibase (Nevisense) Seventh Sense Biosystems Sysmex Chronic Disease Biomarkers Opportunities Extend Across Numerous Therapeutic Areas Anesthesiology Cardiology Endocrinology Gastroenterology Gynecology Hematology Inborn Errors of Metabolism Infectious Diseases Neurology Oncology Rheumatology Microneedle Biomarker Diagnostics Key Therapeutic Sectors Glucose Immune Factors Electrolytes/Potassium Biomarker-enabled Diagnostics Company Profiles For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets

FREMONT, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Lam Research Corp. (Nasdaq: LRCX) today published its annual Environmental, Social, and Governance (ESG) Report detailing the company’s progress in reducing its environmental footprint, driving a healthy and safe workforce, advancing inclusion and diversity, and contributing positively to the broader community. “The world’s response to the devastating pandemic has illuminated how we can transform our planet and intensify the best in humanity when we all work together towards a common goal,” said Tim Archer, president and chief executive officer of Lam Research. “I could not be prouder of the incredible efforts of Lam’s workforce to deliver for our customers and answer the call from our communities in need under the most challenging of circumstances. And in that spirit, I’m pleased to announce our goals detailed in the ESG Report include operating 100% on renewable energy by 2030 and becoming carbon net zero by 2050 to contribute to a more sustainable world.” The company is proactively implementing environmental measures throughout its operations, from operational practices to the design of its products. In 2020, Lam made advances toward its 2025 sustainable operations goals in energy savings, water conservation, waste abatement, and greenhouse gas emissions reduction. This includes goals of reducing scope 1 and scope 2 greenhouse gas emissions by 25% from a 2019 baseline; achieving 12 million kWh in energy savings; conducting waste audits at applicable factory sites; reducing waste to landfill to 0%; and saving 17 million gallons of water in water stressed areas. The recently released report provides an in-depth review of Lam’s ESG goals and strategies, as well as accomplishments in 2020. Key highlights include: Last week, Lam also announced the closing of an inaugural $1.5 billion sustainability-linked credit facility, demonstrating the importance of the company’s ESG goals. Over the credit facility term, Lam will receive a pricing adjustment if the company is above or below performance targets around annual energy savings and maintaining its high standard of employee safety. About Lam Research Lam Research Corporation is a global supplier of innovative wafer fabrication equipment and services to the semiconductor industry. As a trusted, collaborative partner to the world’s leading semiconductor companies, we combine superior systems engineering capability, technology leadership, and unwavering commitment to customer success to accelerate innovation through enhanced device performance. In fact, today, nearly every advanced chip is built with Lam technology. Lam Research (Nasdaq: LRCX) is a FORTUNE 500® company headquartered in Fremont, Calif., with operations around the globe. Learn more at . (LRCX-B) Caution Regarding Forward-Looking Statements Statements made in this press release that are not of historical fact are forward-looking statements and are subject to the safe harbor provisions created by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to but are not limited to: our ESG goals, which may change from time to time; our ability to achieve those goals; the effect that achieving or failing to achieve those goals may have on our business, community, employees, customers, suppliers, and the environment; Lam’s ongoing commitment to COVID-19 relief and recovery efforts; our projections or expectations of how use of our tools and services may reduce resources and materials consumed in the semiconductor manufacturing process as well as in semiconductor equipment manufacturing; our expectations of how cost-effective our CSBG solutions may be to customers and how those solutions may reduce environmental impacts; and Lam’s receipt of a pricing adjustment on our sustainability-linked credit facility. These statements are based on current expectations and are subject to risks, uncertainties, and changes in condition, significance, value and effect including those risks and uncertainties that are described in the documents filed or furnished by us with the Securities and Exchange Commission, including specifically the Risk Factors described in our annual report on Form 10-K for the fiscal year ended June 28, 2020 and quarterly report on Form 10-Q for the quarter ended March 28, 2021. These uncertainties and changes could materially affect the forward-looking statements and cause actual results to vary from expectations in a material way. The Company undertakes no obligation to update the information or statements made in this release. Company Contacts:Libra WhiteMedia Relations(510) 572-7725publicrelations@lamresearch.com Ram GaneshInvestor Relations(510) 572-1615investor.relations@lamresearch.com